Acinetobacter News and Research

RSS

Kenta Biotech and Rentschler Biotechnologie sign agreement to develop antibody against MRSA

Kenta Biotech today announced an agreement with Rentschler Biotechnologie for the development of a fully human monoclonal antibody against methicillin-resistant Staphylococcus aureus (MRSA).

18 Jan 2010

Growing public health threat from surge in drug-resistant strains of acinetobacter

A new study in the journal Infection Control and Hospital Epidemiology reports a surge in drug-resistant strains of Acinetobacter, a dangerous type of bacteria that is becoming increasingly common in U.S. hospitals. This study is being posted online today and will appear in the journal's February print edition.

24 Dec 2009

Two antimicrobial drug developing companies evaluate new approach for treating bacterial infections

Chaperone Technologies, Inc. and MerLion Pharmaceuticals Pte Ltd., both privately-held companies developing new antimicrobial drugs, announced today that they are together evaluating a unique approach for the treatment of resistant and life-threatening bacterial infections.

4 Dec 2009

Cigarettes are widely contaminated with bacteria, reveals study

Cigarettes are "widely contaminated" with bacteria, including some known to cause disease in people, concludes a new international study conducted by a University of Maryland environmental health researcher and microbial ecologists at the Ecole Centrale de Lyon in France.

19 Nov 2009

NanoBio's NB-401 preclinical data to be presented at the 2009 North American Cystic Fibrosis Conference

NanoBio Corporation today announced compelling preclinical data for NB-401, a nebulized nanoemulsion-based agent that kills highly drug-resistant strains of bacteria commonly found in cystic fibrosis patients. Currently there are limited treatment options available that effectively address these resistant bacteria. The study results are being presented today at the 2009 Annual North American Cystic Fibrosis Conference (NACFC) in Minneapolis, Minn.

19 Oct 2009

Study on Lumalier's automated UV device for decontaminating hospital rooms presented at the ICAAC

In a study presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), researchers used a mobile, automated UV device to decontaminate hospital rooms at the Cleveland Veterans Affairs (VA) Medical Center in Ohio and analyzed its ability to remove troublesome bacteria, including C. difficile spores.

12 Oct 2009

U.S. army Phase I STTR contract for Intralytix

Intralytix, Inc. announced today that it has received a U.S. Army Phase I STTR contract supporting the development of a bacteriophage-based probiotic preparation for managing Shigella infections.

9 Oct 2009

Good hand hygiene can eliminate bacterial contamination in computer devices

Although hospital computer equipment can act as a reservoir for pathogenic organisms, including MRSA, researchers writing in the open access journal BMC Infectious Diseases found that bacterial contamination rates from computer equipment were low, possibly as the result of good hand hygiene.

1 Oct 2009

Phase IIa trial results of panobacumab released

Kenta Biotech has presented positive Phase IIa results of its lead drug candidate, panobacumab (KBPA101), showing it is safe and well tolerated in patients with hospital-acquired pneumonia caused by Pseudomonas aeruginosa. The compound, a fully human IgM monoclonal antibody, has the potential to reduce mortality rates.

14 Sep 2009

WRAIR to test Kane Biotech's DispersinB biofilm technology against pathogens in combat trauma wounds

Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development of products that prevent and remove microbial biofilms is pleased to announce that the Company has entered into a Cooperative Research and Development Agreement for Material Transfer (CRADA-MT) with the Walter Reed Army Institute of Research (WRAIR) in Silver Springs, Maryland.

9 Sep 2009

Kane Biotech announces Harvard Medical School's research publication on its DispersinB product

Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms is pleased to announce a recent research publication by Harvard Medical School on their finding of DispersinB® enzyme specific substrate in Acinetobacter baumannii (A. baumannii).

3 Sep 2009

Biologist demystifies Acinetobacter baumannii

Tao Weitao, a researcher in the College of Sciences' Department of Biology at the University of Texas at San Antonio is making great strides in a project that was funded one year ago by the San Antonio Area Foundation. The professor in the South Texas Center for Emerging Infectious Diseases is researching Acinetobacter baumannii, a soil-dwelling bacterium that threatens the health of military personnel in the Middle East and can also infect their family members once the soldiers have returned home following battle.

17 Aug 2009

Machine designed to reduce infections and cut back on expensive "disposables"

Johns Hopkins experts in applied physics, computer engineering, infectious diseases, emergency medicine, microbiology, pathology and surgery have unveiled a 7-foot-tall, $10,000 shower-cubicle-shaped device that automatically sanitizes in 30 minutes all sorts of hard-to-clean equipment in the highly trafficked hospital emergency department.

30 Jul 2009

Bacteria create aquatic superbugs in waste treatment plants

For bacteria in wastewater treatment plants, the stars align perfectly to create a hedonistic mating ground for antibiotic-resistant superbugs eventually discharged into streams and lakes.

13 May 2009

War wounded at risk for superbugs

Soldiers who survive severe injuries on battlefields such as those in Iraq and Afghanistan can be at risk from developing infections of their wounds with multidrug resistant bacteria.

30 Mar 2009

New bone cement may prevent amputations

Old technologies, bone cement and a well known antibiotic, may effectively fight an emerging infection in soldiers with compound bone fractures, according to a study published online in the Journal of Orthopedic Research.

29 Jan 2009

Genes involved in antibiotic resistance vary within a species

The recent emergence of multidrug resistance (MDR) in Acinetobacter baumannii, a bacteria that causes infections primarily among seriously ill patients in the intensive care unit who may have reduced immune systems, has raised concern in health care settings worldwide.

16 Dec 2008

Six bad bugs increasingly escaping effects of antibiotics

Infectious disease experts warn that new drugs are urgently needed to treat six drug-resistant bacteria that cause most hospital infections and increasingly escape the effects of antibiotics.

1 Dec 2008

Clear seasonal variation in bacterial infections

In the same way that winter is commonly known to be the "flu season," a new study suggests that the dog days of summer may well be the "bacterial infection" season.

26 Nov 2008

Accelr8 announces study results with BACcel diagnostic system for broad resistance in gram-negative pathogens

Accelr8 Technology Corporation announced study results today that were presented at the joint sessions of the 48 th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC, www.icaac.org) and the Infectious Diseases Society of America (IDSA, www.idsociety.org), October 25-29 in Washington, DC.

7 Nov 2008